Breaking News Instant updates and real-time market news.

BPY

Brookfield Property

$20.68

-0.22 (-1.05%)

, APRN

Blue Apron

$1.60

-0.12 (-7.00%)

08:45
10/02/18
10/02
08:45
10/02/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Brookfield Property (BPY) 4.08% +0.67, Blue Apron (APRN) 18.88% +0.35, GTx (GTXI) 4.71% +0.06, Camping World (CWH) 5.93% +0.05, Direxion Daily Semiconductor Bull 3X Shares (SOXL) 7.21% +0.04, Viking Therapeutics (VKTX) 2.48% +0.04, Deutsche Bank (DB) 0.46% +0.04, iShares Goldman Sachs Software Index Fund (IGV) 2.00% +0.03, iQiyi (IQ) 2.54% +0.03, and Realogy (RLGY) 0.90% +0.02.

BPY

Brookfield Property

$20.68

-0.22 (-1.05%)

APRN

Blue Apron

$1.60

-0.12 (-7.00%)

GTXI

GTx

$1.51

-0.055 (-3.53%)

CWH

Camping World

$20.00

-1.3 (-6.10%)

VKTX

Viking Therapeutics

$16.21

-1.21 (-6.95%)

DB

Deutsche Bank

$11.24

-0.115 (-1.01%)

IQ

iQIYI

$26.89

-0.17 (-0.63%)

RLGY

Realogy

$20.52

-0.12 (-0.58%)

  • 15

    Oct

  • 01

    Nov

  • 06

    Nov

BPY Brookfield Property
$20.68

-0.22 (-1.05%)

03/27/18
RHCO
03/27/18
DOWNGRADE
Target $23.5
RHCO
Hold
GGP downgraded to Hold from Buy at SunTrust
SunTrust analyst Ki Bin Kim downgraded GGP (GGP) to Hold from Buy and lowered the price target to $23.50 from $26 after Brookfield Property Partners (BPY) agreed to acquire the company at that price. While the improved offer represents only a "half-step" forward toward more equitable valuation relative to prior approach, the analyst ultimately expects this deal to close.
03/27/18
JPMS
03/27/18
DOWNGRADE
Target $23.5
JPMS
Neutral
GGP downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Mueller downgraded GGP (GGP) to Neutral and lowered his price target for the shares to $23.50 from $25.50. The analyst is shuffling his ratings in the REIT space following GGP's takeout by Brookfield Property Partners (BPY). He believes the price paid by Brookfield makes his "bullish mall thesis harder to push."
03/27/18
ADAM
03/27/18
UPGRADE
ADAM
Buy
Brookfield Property upgraded to Buy from Hold at Canaccord
03/27/18
03/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. BB&T (BBT) upgraded to Buy from Neutral at B. Riley FBR and to Outperform from Market Perform at Wells Fargo. 2. Aratana Therapeutics (PETX) upgraded to Buy from Hold at Stifel with analyst Jonathan Block saying the early traction for Entyce, which was launched October 2017, has increased his conviction that the drug will act as the main revenue driver for Aratana in coming years. 3. Prologis (PLD) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Mueller saying he is shuffling his ratings in the REIT space following GGP's (GGP) takeout by Brookfield Property Partners (BPY). 4. Brookfield Property (BPY) upgraded to Buy from Hold at Canaccord. 5. Roku (ROKU) upgraded to Neutral from Sell at Citi with analyst Mark May citing valuation for the upgrade following the stock's recent underperformance, but admits the upcoming lock-up expiration could serve as a negative catalyst. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
APRN Blue Apron
$1.60

-0.12 (-7.00%)

08/03/18
ADAM
08/03/18
NO CHANGE
Target $6
ADAM
Buy
Blue Apron downside risk limited at current levels, says Canaccord
Canaccord analyst Michael Graham noted Blue Apron reported mixed Q2 results and said the guidance suggests the revenue impact from the "transition" year will get worse in Q3 and Q4 before it gets better. Despite that, he sees reasons to be optimistic heading into 2019, including a likely return to intensive marketing and upside from nascent multi-channel offerings. Graham maintained his Buy rating and lowered his price target to $6 from $8 on Blue Apron shares.
02/16/18
02/16/18
UPGRADE

Neutral
Blue Apron upgraded to Neutral on retail partnership potential at Northcoast
As previously reported, Northcoast analyst Charles Cerankosky upgraded Blue Apron to Neutral from Sell. He noted that management is suggesting the company could be at breakeven EBITDA by year end, though he "is far less optimistic." Still, given the pressure of its negative cash flow, he thinks Blue Apron will explore a retail distribution partnership, which could have a potential headline benefit. However, Cerankosky added that he expects that even if such a retail distribution partnership was struck, he believes "disappointing sales at retail would likely force such a relationship to die quickly."
02/16/18
NRCS
02/16/18
UPGRADE
NRCS
Neutral
Blue Apron upgraded to Neutral from Sell at Northcoast
07/13/18
KEYB
07/13/18
NO CHANGE
KEYB
Sector Weight
Blue Apron's Costco test 'progressign well,' says KeyBanc
KeyBanc analyst Edward Yruma told investors in a research note that Blue Apron's (APRN) expansion of its on-demand meal kits at Costco (COST) continues to progress well, spreading to the Midwest and Southern areas of the U.S., and that this reinforces his increasingly constructive stance. While still small compared to direct-to-consumer, Yruma says the kits provide an opportunity for Blue Apron to conveniently reach new customers with a best-in-class national partner and that its upside prospects are becoming more favorable. Yruma maintains a Sector Weight rating, says valuation looks reasonable, and adds that operational issues at the Linden fulfillment centers are "largely in the past."
GTXI GTx
$1.51

-0.055 (-3.53%)

09/21/18
BARD
09/21/18
DOWNGRADE
BARD
Neutral
GTx downgraded to Neutral from Outperform at Baird
09/21/18
STFL
09/21/18
DOWNGRADE
STFL
Hold
GTx downgraded to Hold from Buy at Stifel
09/21/18
09/21/18
DOWNGRADE
Target $2

Hold
GTx downgraded to Hold, price target slashed to $2 at Stifel
As previously reported, Stifel analyst Adam Walsh downgraded GTx to Hold from Buy after the Phase 2b ASTRID trial evaluating enobosarm in women with SUI did not achieve statistical significance on its primary endpoint. Following the trial failure, Walsh would expect the SUI program to be discontinued and for the stock to trade at or around cash levels of about $2 per share. Accordingly, the analyst lowered his price target on GTx shares to $2 from $45.
09/21/18
RAJA
09/21/18
NO CHANGE
Target $43
RAJA
Outperform
Raymond James says Viking volatility on GTx trial failure would be chance to buy
Raymond James analyst Steven Seedhouse would be a buyer on any volatility in Viking Therapeutics (VKTX) after GTx (GTXI) announced its Phase 2 ASTRID study testing enobosarm in women with SUI failed to achieve its primary endpoint. Viking has not ever tested VK5211 in SUI, but there had appeared to be solid early clinical and preclinical rationale for the indication, Seedhouse tells investors. Viking is not yet developing its SARM VK5211 in SUI and VK5211 is not in his model for either SUI or hip fracture recovery, so the failure of ASTRID really doesn't have immediate or direct negative readthrough to Viking, Seedhouse added. He maintains an Outperform rating and $43 price target on Viking shares, which are down 1% to $18.73 in early trading.
CWH Camping World
$20.00

-1.3 (-6.10%)

05/09/18
BMOC
05/09/18
NO CHANGE
Target $42
BMOC
Outperform
Camping World price target lowered to $42 from $62 at BMO Capital
BMO Capital analyst Gerrick Johnson lowered his price target on Camping World to $42 after its "slight" earnings miss in Q1 along with trailing comps relative to the overall market. The analyst notes that investors' concerns around the delay of Gander Outdoors rollout has been heightened but keeps his Outperform rating, expecting the RV industry conditions to remain strong with "normalized" results over the course of the year.
08/15/18
JPMS
08/15/18
NO CHANGE
Target $36
JPMS
Overweight
Camping World price target lowered to $36 from $42 at JPMorgan
JPMorgan analyst Ryan Brinkman reiterated an Overweight rating on Camping World but cut his price target to $36 from $42 to reflect lowered estimates and a lower trading multiple. Although the RV industry is cyclical, Brinkman expects that with the current strong industry backdrop, "solid" M&A activities, earnings will likely outperform over the next several years.
08/17/18
NRCS
08/17/18
NO CHANGE
NRCS
Northcoast says channel checks pointing to weakening RV demand
Northcoast analyst Seth Woolf said he has become incrementally more cautious on the Recreation & Leisure Products group as his channel checks are pointing to weakening retail demand. While he believes "the buy-side is clearly expecting to see weak wholesale numbers in the coming months," Woolf also contends that the magnitude of declines could be a surprise. He maintains a Buy rating on Camping World (CWH) and Neutral ratings on LCI Industries (LCII), Thor Industries (THO) and Winnebago (WGO).
08/21/18
BMOC
08/21/18
NO CHANGE
Target $36
BMOC
Outperform
Camping World price target lowered to $36 from $42 at BMO Capital
BMO Capital analyst Gerrick Johnson lowered his price target on Camping World to $36 but kept his Outperform rating after its Investor Day presentation. The analyst notes that his prior concerns with the Gander Mountain asset purchase have been realized when the company recently cut its EBITDA guidance, however he also sees its change in the retail strategy to be "accretive" next year with solid growth potential going into 2019. Specifically, the analyst is positive on Camping World's plans to use Gander Outdoors as a "back door" to bring its RV dealerships into underpenetrated areas without the capital investment that would be needed at acquired dealerships, adding that the multiple on the stock had previously been negatively impacted by the investors' confusion over the company's plans.
VKTX Viking Therapeutics
$16.21

-1.21 (-6.95%)

10/01/18
HCWC
10/01/18
NO CHANGE
Target $31
HCWC
Buy
Viking Therapeutics price target raised to $31 from $28 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Viking Therapeutics to $31 after the company and investigators presented updated VK5211 data in an oral plenary presentation at the American Society of Bone and Mineral Research. The key takeaways from the VK5211 Phase 2 data in hip fracture patients include: VK5211 produces significant muscle growth in hip fracture patients, VK5211-treated patients experienced overall weight gain, the six-minute walk test demonstrated a trend favoring the treatment arms and the tolerability profile in elderly patients was encouraging with no treatment-emergent adverse events, Pantginis tells investors in a research note. The analyst keeps a Buy rating on Viking Therapeutics.
10/01/18
WBLR
10/01/18
NO CHANGE
WBLR
Outperform
Viking Therapeutics data increase partnership potential, says William Blair
Viking Therapeutics over the weekend at the American Society for Bone and Mineral Research annual meeting presented full data from the positive Phase II study with VK5211 for the treatment of patients recovering from hip fracture, William Blair analyst Andy Hsieh tells investors in a research note. While top-line results were released late last year, there were incrementally positive data points, including 6-minute walk test improvements and "intriguing" fat mass reduction, Hsieh writes. He believes the updated clinical profile bodes well for the partnership potential for VK5211 and eventual market uptake. The analyst continues to hold a bullish view on Viking Therapeutics shares with an Outperform rating.
10/02/18
HCWC
10/02/18
NO CHANGE
Target $280
HCWC
Buy
Ligand price target raised to $280 from $270 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $280 after Viking Therapeutics (VKTX) and investigators presented updated VK5211 data in an oral plenary presentation at the American Society of Bone and Mineral Research meeting. VK5211 produces significant muscle growth in hip fracture patients and treated patients experienced overall weight gain, with loss of body fat, Pantginis tells investors in a research note. The analyst believes the chances for an outright acquisition of Viking has increased with VK2809 and VK5211 having the potential to address very large markets. He keeps a Buy rating on Ligand.
DB Deutsche Bank
$11.24

-0.115 (-1.01%)

06/01/18
RBCM
06/01/18
DOWNGRADE
RBCM
Underperform
Deutsche Bank downgraded to Underperform from Sector Perform at RBC Capital
08/10/18
MSCO
08/10/18
DOWNGRADE
MSCO
Underweight
Deutsche Bank downgraded to Underweight from Equal Weight at Morgan Stanley
08/10/18
08/10/18
DOWNGRADE

Underweight
Morgan Stanley cuts Deutsche Bank to Underweight on limited top-line visibility
As previously reported, Morgan Stanley analyst Magdalena Stoklosa downgraded Deutsche Bank to Underweight from Equal Weight, stating that while she gives management "full credit" for its cost cutting efforts, it is hard to have any visibility on the top line. She assumes 2018-20 revenue CAGR of just 1.5%, which is below the average for Eurozone banks and below managements target of 4%. While recognizing the risk of downgrading Deutsche Bank "at the bottom," Stoklosa sees current conditions as unlikely to be conducive to a near-term re-rating, she tells investors. She has an EUR9 target on the bank's shares.
08/13/18
BOFA
08/13/18
DOWNGRADE
Target $9
BOFA
Underperform
Deutsche Bank downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Andrew Stimpson downgraded Deutsche Bank to Underperform from Neutral saying he expects the earnings downgrade cycle to continue given CIB revenue headwinds.
IQ iQIYI
$26.89

-0.17 (-0.63%)

08/01/18
FBCO
08/01/18
DOWNGRADE
FBCO
Neutral
iQIYI downgraded to Neutral from Outperform at Credit Suisse
08/02/18
GSCO
08/02/18
DOWNGRADE
GSCO
Neutral
iQIYI downgraded to Neutral from Buy at Goldman Sachs
08/02/18
08/02/18
DOWNGRADE
Target $30

Neutral
iQIYI downgraded to Neutral on valuation at Goldman Sachs
As previously reported, Goldman Sachs downgraded iQIYI to Neutral from Buy with a $30 price target, up from $23. Analyst Piyush Mubayi raised estimates to reflect an improved margin and better ARPU outlook following the Q2 report, but believes the recent share appreciation reflects upside potential.
09/04/18
LYON
09/04/18
INITIATION
Target $36.5
LYON
Buy
iQIYI initiated with a Buy at CLSA
CLSA initiated iQIYI with a Buy and $36.50 price target.
RLGY Realogy
$20.52

-0.12 (-0.58%)

12/06/17
JPMS
12/06/17
NO CHANGE
Target $30
JPMS
Neutral
Realogy price target lowered to $30 from $37 at JPMorgan
JPMorgan analyst Anthony Paolone believes estimates for Realogy Holdings have further downside and he dropped his price target for the shares to $30. U.S. tax reform, while having a positive implication on the company's corporate tax rate, has potentially negative implications on the housing backdrop, Paolone tells investors in a research note. Further, the analyst thinks "significant competition" remains for top agents that could continue to put pressure on splits. He keeps a Neutral rating on Realogy shares.
12/15/17
JPMS
12/15/17
DOWNGRADE
Target $28
JPMS
Underweight
Realogy downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Anthony Paolone downgraded Realogy Holdings to Underweight and lowered his price target for the shares to $28 from $30 in conjunction with his 2018 REIT outlook.
02/28/18
DBAB
02/28/18
NO CHANGE
Target $35
DBAB
Buy
Realogy shares to build on yesterday's rally, says Deutsche Bank
Deutsche Bank analyst Kevin McVeigh expects shares of Realogy to be build yesterday's rally in the coming weeks and months. In a post-earnings research note titled "Buy non distressed at distressed value," the analyst maintains a Buy rating on the shares with a $35 price target. The analyst looks for "multiple positive 2018 catalysts", namely the Cartus restructuring, split normalization and new CEO, to drive upside to the shares.
02/27/18
SPHN
02/27/18
NO CHANGE
Target $33
SPHN
Overweight
Stephens buyers of Realogy following earnings report
Stephens analyst John Campbell said he would be buying Realogy shares following the company's Q4 report, Q1 guidance and 2018 commentary, noting that management was "adamant" on the earnings call that Q1 trends did not fully reflect their view of EBITDA progress in the rest of the fiscal year. The company thinks EBITDA in Q2-Q4 of FY18 will be flat to better year-over-year, noted Campbell, who keeps an Overweight rating and $33 price target on Realogy shares.

TODAY'S FREE FLY STORIES

VZ

Verizon

$56.74

1.78 (3.24%)

10:41
10/23/18
10/23
10:41
10/23/18
10:41
Recommendations
Verizon analyst commentary  »

Verizon more or less…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

  • 13

    Nov

BAC

Bank of America

$26.40

-0.96 (-3.51%)

10:40
10/23/18
10/23
10:40
10/23/18
10:40
Options
BofA calls outpace puts 13:1 »

BofA calls outpace puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

GLT

Glatfelter

$18.20

-0.295 (-1.60%)

10:40
10/23/18
10/23
10:40
10/23/18
10:40
Hot Stocks
Glatfelter's Composite Fibers unit announces 7% price increase »

Glatfelter announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

10:40
10/23/18
10/23
10:40
10/23/18
10:40
General news
Fed Policy Outlook: the markets will look for any sign the FOMC is reacting »

Fed Policy Outlook: the…

RH

RH

$110.05

0.95 (0.87%)

, MO

Altria Group

$60.96

-0.35 (-0.57%)

10:35
10/23/18
10/23
10:35
10/23/18
10:35
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…

RH

RH

$110.05

0.95 (0.87%)

MO

Altria Group

$60.96

-0.35 (-0.57%)

GRTS

Gritstone Oncology

$16.10

0.93 (6.13%)

CZR

Caesars

$8.98

-0.51 (-5.37%)

TEAM

Atlassian

$70.16

-2.46 (-3.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

EBAY

eBay

$27.72

-0.76 (-2.67%)

, DISH

Dish

$31.99

-2.67 (-7.70%)

10:35
10/23/18
10/23
10:35
10/23/18
10:35
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…

EBAY

eBay

$27.72

-0.76 (-2.67%)

DISH

Dish

$31.99

-2.67 (-7.70%)

INN

Summit Hotel Properties

$11.12

-0.74 (-6.24%)

STAY

Extended Stay America

$16.28

-1.2 (-6.87%)

LBRT

Liberty Oilfield Services

$16.14

-2.18 (-11.90%)

MLCO

Melco Resorts & Entertainment

$16.91

-0.83 (-4.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 01

    Nov

  • 03

    Mar

VIA

Viacom

$36.01

-0.6 (-1.64%)

, VIAB

Viacom

$32.66

-0.34 (-1.03%)

10:35
10/23/18
10/23
10:35
10/23/18
10:35
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…

VIA

Viacom

$36.01

-0.6 (-1.64%)

VIAB

Viacom

$32.66

-0.34 (-1.03%)

SNPS

Synopsys

$88.80

-0.07 (-0.08%)

CDNS

Cadence Design

$44.34

3.72 (9.16%)

PII

Polaris Industries

$86.99

-5.63 (-6.08%)

AMD

AMD

$24.35

-0.69 (-2.76%)

NXPI

NXP Semiconductors

$74.97

-1.5 (-1.96%)

CMG

Chipotle

$429.89

-1.36 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 01

    Nov

  • 06

    Dec

  • 13

    Dec

  • 12

    Mar

MGM

MGM Resorts

$24.84

-1.27 (-4.86%)

10:30
10/23/18
10/23
10:30
10/23/18
10:30
Options
Call spread in MGM as shares fall to 52-week lows »

Call spread in MGM as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

10:30
10/23/18
10/23
10:30
10/23/18
10:30
General news
U.S. equities rotated sharply lower »

U.S. equities rotated…

TSLA

Tesla

$275.35

14.32 (5.49%)

10:29
10/23/18
10/23
10:29
10/23/18
10:29
Hot Stocks
Tesla races as short-seller Citron reverses course, goes long »

Citron Research, best…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 13

    Dec

TOT

Total

$58.38

-1.47 (-2.46%)

10:28
10/23/18
10/23
10:28
10/23/18
10:28
Hot Stocks
Total CEO justifies appearance at Saudi investment conference »

Total CEO Patrick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
10/23/18
10/23
10:25
10/23/18
10:25
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

10:25
10/23/18
10/23
10:25
10/23/18
10:25
Conference/Events
The FCC to hold a meeting »

Open Commission Meeting…

JBLU

JetBlue

$16.59

0.02 (0.12%)

10:20
10/23/18
10/23
10:20
10/23/18
10:20
Hot Stocks
Breaking Hot Stocks news story on JetBlue »

JetBlue says expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ARNC

Arconic

$20.73

-0.72 (-3.36%)

10:20
10/23/18
10/23
10:20
10/23/18
10:20
Options
Active trading in Arconic call options including a notable three-way spread »

Active trading in Arconic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

JBLU

JetBlue

$16.56

-0.01 (-0.06%)

10:18
10/23/18
10/23
10:18
10/23/18
10:18
Hot Stocks
JetBlue says Q4 booking trends 'encouraging' »

Says executing plan to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/23/18
10/23
10:17
10/23/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
10/23/18
10/23
10:16
10/23/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$44.84

-0.91 (-1.99%)

10:15
10/23/18
10/23
10:15
10/23/18
10:15
Options
Cisco put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

10:15
10/23/18
10/23
10:15
10/23/18
10:15
General news
U.S. Richmond Fed's manufacturing index dove 14 points to 15 in October »

U.S. Richmond Fed's…

10:15
10/23/18
10/23
10:15
10/23/18
10:15
General news
Treasury Action: yields extended their retreat »

Treasury Action: yields…

CLF

Cleveland-Cliffs

$10.96

-0.37 (-3.27%)

10:08
10/23/18
10/23
10:08
10/23/18
10:08
Recommendations
Cleveland-Cliffs analyst commentary  »

Vertical sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$96.98

-0.16 (-0.16%)

, SPWR

SunPower

$6.64

-0.1 (-1.48%)

10:08
10/23/18
10/23
10:08
10/23/18
10:08
Hot Stocks
Walmart, SunPower announce 23-megawatt solar agreement »

Walmart (WMT) announced…

WMT

Walmart

$96.98

-0.16 (-0.16%)

SPWR

SunPower

$6.64

-0.1 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 30

    Oct

  • 15

    Nov

REV

Revlon

$24.60

-0.09 (-0.36%)

10:06
10/23/18
10/23
10:06
10/23/18
10:06
Periodicals
Mox Reports repeats long call on Revlon »

MoxReports tweeted:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$81.75

-1.22 (-1.47%)

10:05
10/23/18
10/23
10:05
10/23/18
10:05
Hot Stocks
Fortinet paid $18M in initial consideration for ZoneFox »

As previously reported,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.